A summary of agents in late-stage development for the prevention and/or treatment of osteoporosis.
Celltrion USA Seeks Approval for Actemra Biosimilar
Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.
FDA Approves First Biosimilar of Arthritis Med Actemra
Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.
Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA
Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.
FDA Approves Kevzara for Inflammatory Rheumatic Disease
Kevzara is the first biologic to treat patients with polymyalgia rheumatica (PMR). It is also approved to treat rheumatoid arthritis.
Will the Biosimilar Amjevita Lower Costs?
The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.
First Humira Biosimilar is Now Available
Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.
2 Commerce Drive Cranbury, NJ 08512